Understanding the mechanisms and management of parkinson’s disease. A comprehensive review of current research and therapeutic approaches

Nº de DOI:10.34896/RSI.2025.43.43.001

AUTHORS

1. Nataly Paola Lozada Riera. Medical Surgeon. Master in Aesthetics. Attached to the Loreto Type B Health Centre. Independent Researcher of the Department of Research and Teaching Matilde Hidalgo of Procel. Graduate of the Autonomous Regional University of the Andes. (Pujilí-Ecuador). https://orcid.org/0009-0003-0026-5260
2. Edison Antonio Giler Ortiz. General Practitioner. Attached to the Baba Hospital. Graduate of the State University of Guayaquil. (Guayaquil-Ecuador). https://orcid.org/0009-0004-4900-427X
3. Daniela Patricia Galarza Alvear. Medical Surgeon. Attached to the Eugenio Espejo Specialities Hospital. Graduate of the University of the Americas. (Quito-Ecuador). https://orcid.org/0009-0002-6029-9270
4. Orlyn Javier Izquieta Villamar. General Practitioner. Attached to Private Clinics of Ecuador. Graduated from the Catholic University of Cuenca. (Cuenca -Ecuador). https://orcid.org/0009-0004-5056-1735
5. Michel Estephania Falconi Chávez. General Practitioner. Attached to the San Pedro de Riobamba Basic Hospital. Graduate of the National University of Chimborazo. (Riobamba-Ecuador). https://orcid.org/0009-0004-5017-3986

ABSTRACT

This comprehensive review aims to synthesize current research and therapeutic approaches, offering a deeper understanding of PD’s mechanisms and a critical evaluation of existing and emerging treatments that hold promise for improving patient outcomes and quality of life.

KEY WORDS

Parkinson’s disease pathophysiology, dopaminergic degeneration, alpha-synuclein, Parkinson’s treatment strategies, and non-motor symptoms of Parkinson’s.

ABSTRACTO

Esta revisión integral tiene como objetivo sintetizar los enfoques terapéuticos y de investigación actuales, ofreciendo una comprensión más profunda de los mecanismos de la EP y una evaluación crítica de los tratamientos existentes y emergentes que prometen mejorar los resultados de los pacientes y la calidad de vida.

PALABRAS CLAVE

Fisiopatología de la enfermedad de Parkinson, degeneración dopaminérgica, alfa-sinucleína, estrategias de tratamiento del Parkinson y síntomas no motores del Parkinson.

INTRODUCTION

Parkinson’s Disease (PD) represents a complex neurodegenerative disorder characterized by progressive motor and non-motor symptoms, fundamentally altering the lives of millions worldwide. Understanding the multifaceted mechanisms underlying PD is crucial, as the disease is primarily marked by the degeneration of dopaminergic neurons in the substantia nigra, leading to characteristic symptoms such as tremors, rigidity, and bradykinesia. Current research illuminates the intricate interplay between genetic predispositions—where mutations in genes such as SNCA and LRRK2 have been implicated—and environmental factors, including exposure to pesticides and heavy metals, which may synergistically elevate the risk of developing this debilitating condition. Recent advancements in our understanding of PD pathology have unveiled novel biomarkers that offer promising avenues for early diagnosis and intervention, while innovative models, such as induced pluripotent stem cells and transgenic animal models, provide critical insights into the disease’s progression and potential therapeutic targets. In terms of management, a range of pharmacological treatments, including dopaminergic medications like levodopa, are currently employed to alleviate symptoms; however, the efficacy of these treatments often diminishes over time, necessitating the exploration of non-pharmacological therapies such as physical rehabilitation and cognitive interventions. As the field moves forward, it is imperative to focus on the development of disease-modifying therapies that not only address symptomatic relief but also target the underlying pathophysiological processes of Parkinson’s Disease.

OBJECTIVE

Synthesise current research and therapeutic approaches, providing a deeper understanding of the mechanisms of PD and a critical evaluation of existing and emerging treatments that hold promise for improving patient outcomes and quality of life.

METHODOLOGY

This scientific review investigates the mechanisms and management of Parkinson’s disease (PD), focusing on current research and therapeutic approaches. A comprehensive search of peer-reviewed literature is conducted using databases such as PubMed, Scopus, and Web of Science. Keywords including “Parkinson’s disease pathophysiology,” “dopaminergic degeneration,” “alpha-synuclein,” “Parkinson’s treatment strategies,” and “non-motor symptoms of Parkinson’s” are used to identify relevant articles. The review includes studies published over the last 20 years to ensure a balance of foundational knowledge and the most recent advancements in the field.

Studies included in this review cover a broad spectrum of topics, including the underlying pathophysiological mechanisms of PD, such as alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. Genetic studies exploring mutations in genes like SNCA, LRRK2, and PARKIN are also analyzed to understand hereditary contributions and their implications for targeted therapies. Clinical research on motor and non-motor symptoms, including bradykinesia, rigidity, cognitive decline, and depression, is included to provide a holistic view of disease presentation.

Therapeutic approaches are a central focus, and the review evaluates pharmacological treatments, including levodopa, dopamine agonists, monoamine oxidase inhibitors, and novel agents targeting non-dopaminergic pathways. Non-pharmacological strategies, such as deep brain stimulation (DBS), physical therapy, and dietary interventions, are also examined for their role in improving patient outcomes. Emerging treatments, including gene therapy, stem cell-based approaches, and immunotherapy targeting alpha-synuclein, are reviewed to highlight potential future directions in PD management.

Each study is critically appraised for methodological rigor, sample size, and relevance to clinical practice. Data are organized thematically, covering disease mechanisms, symptomatology, and treatment modalities. Quantitative findings, such as changes in Unified Parkinson’s Disease Rating Scale (UPDRS) scores, side effect profiles, and patient-reported outcomes, are synthesized to identify trends and gaps in current knowledge.

RESULTS

Mechanisms of Parkinson’s Disease:

What are the primary neurological changes in Parkinson’s Disease?

The primary neurological changes in Parkinson’s Disease are fundamentally rooted in the degeneration of dopaminergic neurons, particularly within the substantia nigra, a critical region of the brain responsible for movement control^1,2,3. These neurons’ degeneration leads to a significant reduction in dopamine production, an essential neurotransmitter that facilitates communication between different brain regions related to motor function^1,4. The substantial loss of dopamine-producing cells—often over 80%—in the substantia nigra pars compacta (SNpc) correlates directly with the onset of Parkinson’s symptoms, underscoring the importance of these neurons in maintaining motor function^1,2. This dopamine deficiency extends to the striatum, further disrupting the cortico-striatal circuits and impairing motor coordination³. As a result, the brain’s ability to effectively control muscle movements is severely compromised, leading to the characteristic motor symptoms observed in individuals with Parkinson’s Disease⁴. Thus, addressing these neurological changes through neuroprotective strategies and therapeutic interventions is crucial to mitigate the progression and impact of Parkinson’s Disease.

How do genetic factors contribute to the development of Parkinson’s Disease?

Genetic factors play a crucial role in the development of Parkinson’s disease (PD), with contributions ranging from highly penetrant DNA variants to those that slightly increase the lifetime risk of the disease⁵. While some rare DNA variants with high effect sizes are linked to monogenic or familial forms of PD, more common variants with smaller effects are often identified in sporadic cases⁵. These genetic variations can be found across numerous loci involved in cellular processes such as protein aggregation, membrane trafficking, lysosomal autophagy, and immune responses, which are all pathways implicated in PD pathology⁶. Notably, the PARK7, PINK1, or PRKN genes can contribute to an autosomal recessive pattern of inheritance for PD, requiring both copies of the gene in each cell to have a variant for the disease to manifest⁴. Despite these insights, the individual contribution of a single genetic factor to the development of PD is minimal, underscoring the importance of novel prognostic indices that account for the cumulative nature of these genetic risk factors⁶. As research continues to evolve, a comprehensive understanding of the genetic underpinnings of PD will be vital for identifying individuals at the highest risk and developing targeted therapies that could slow or prevent the progression of the disease^5,6.

What role do environmental factors play in Parkinson’s Disease onset?

The intricate relationship between genetic predisposition and environmental factors plays a crucial role in the onset of Parkinson’s Disease (PD), as evidenced by various experimental models that demonstrate gene-environment interactions⁷. Notably, studies involving Parkin knockout mice illustrate heightened sensitivity to environmental toxins such as rotenone, underscoring how genetic mutations can exacerbate the impact of these toxins⁷. This sensitivity points to the broader implication that individuals with certain genetic backgrounds are more vulnerable to environmental exposures, which can significantly influence disease progression and severity⁸. Moreover, primary cortical neurons and mesencephalic dopaminergic neurons from young knock-in mice show increased susceptibility to environmental challenges, further emphasizing the role of gene-environment interactions in PD onset⁷. These findings suggest that the interaction between genetic and environmental factors is not merely additive but potentially synergistic, leading to a compounded risk that is higher than the sum of individual risks. Consequently, there is a pressing need to incorporate these insights into public health strategies and disease prevention agendas to address modifiable risk factors, including environmental influences, thus opening avenues for early intervention and potentially reducing the burden of PD⁸.

Current Research in Parkinson’s Disease:

What are the latest findings in Parkinson’s Disease pathology?

The latest findings in Parkinson’s disease pathology are fundamentally reshaping our understanding of the disease by highlighting the potential roles of tau pathology and neuroinflammation. Traditionally, alpha-synuclein has been regarded as the primary marker for Parkinson’s disease, but recent research challenges this view by demonstrating that tau pathology might contribute significantly to the degeneration of dopamine-producing neurons, independent of alpha-synuclein⁹. This revelation is pivotal as it expands the scope of research beyond the conventional focus on alpha-synuclein, suggesting that tau may be an early player in the manifestation of Parkinson’s cardinal motor symptoms⁹. Additionally, the connection between neuroinflammation and Parkinson’s disease pathology has gained traction, with studies indicating that neuroinflammation might be a crucial component of the disease’s progression¹⁰. Understanding these relationships not only broadens the biological framework of Parkinson’s disease but also opens new avenues for therapeutic interventions, potentially leading to earlier diagnosis and more targeted treatments¹¹. Such advancements underscore the necessity for continued investigation into these emerging pathological aspects, as they hold the promise of transforming patient care and treatment strategies for Parkinson’s disease¹¹.

How are biomarkers being used in Parkinson’s Disease research?

In Parkinson’s disease research, biomarkers play a pivotal role in advancing our understanding and management of the condition, particularly through early detection and diagnosis. A significant breakthrough in this field has been the identification of abnormal alpha-synuclein as a biomarker, which is central to the pathology of Parkinson’s disease due to its association with cell loss in the brain¹². This biomarker not only aids in detecting Parkinson’s disease in individuals who have already been diagnosed but also serves as a tool for identifying those at high risk of developing the disease even before symptoms manifest¹³. The utility of abnormal alpha-synuclein extends to improving the precision of early diagnosis, which is crucial given the substantial loss of dopamine-producing cells needed for symptoms to appear¹². By facilitating earlier intervention, these biomarkers hold promise in potentially altering the course of the disease, underscoring the need for continued research and development in this area.

What innovative models are used to study Parkinson’s Disease?

To advance the study of Parkinson’s Disease beyond genetic risk factors, innovative models have been developed that offer new insights into disease mechanisms and progression. Notably, the research spearheaded by Weill Cornell Medicine has resulted in a preclinical model using three-month-old mice lacking rod-cell VPS35, which mimics the progression of Parkinson’s Disease more closely to human pathology than previous models^14,15. This model is particularly valuable because it does not involve artificial modifications of the alpha-synuclein protein, a common feature in other models, thus providing a more accurate representation of the disease process¹⁴. The unique platform established by this model allows researchers to delve into the early stages of Parkinson’s, which could significantly enhance understanding and lead to the development of more effective management strategies¹⁵. These advancements underscore the importance of innovative research approaches in improving outcomes for individuals affected by Parkinson’s Disease¹⁵. As researchers continue to refine these models, they hold great promise for testing potential therapies and ultimately alleviating the burden of this complex neurodegenerative disorder¹⁴.

Therapeutic Approaches for Parkinson’s Disease

What are the current pharmacological treatments for Parkinson’s Disease?

Pharmacological treatments for Parkinson’s Disease (PD) primarily aim to manage motor symptoms such as tremors and movement problems, as there are no available therapies that modify the disease progression,.Levodopa is the most commonly prescribed medication, and its use becomes necessary for most patients as the disease advances.This drug, along with other dopaminergic agents, works by compensating for the loss of dopamine in the brain, particularly in the striatum, which is central to motor control and is depleted in PD patients¹⁶. While these medications can significantly alleviate motor symptoms, they do not address the non-motor symptoms and can lead to adverse effects, especially with long-term use. The complexity of managing PD is further compounded by the fact that these drugs, although effective at controlling symptoms, do not alter the disease’s natural course¹⁶. This underscores the importance of ongoing research into emerging treatments and drug repurposing, which hold promise for offering more comprehensive management strategies for PD in the future.

How effective are non-pharmacological therapies in managing Parkinson’s Disease symptoms?

Non-pharmacological therapies have emerged as significant contributors in the management of both motor and non-motor symptoms of Parkinson’s Disease (PD), providing a complementary approach to pharmacological treatments. These therapies, such as acupuncture and exercise, are particularly noteworthy for their dual role in addressing both the symptomatic and potential disease-modifying aspects of PD^17,18. Acupuncture, for instance, has demonstrated efficacy in alleviating symptoms by affecting neurotransmitters and endogenous substances, which may relieve non-motor symptoms like insomnia and depression¹⁷. Additionally, exercise therapy not only aids in reducing pain perception but also helps in decreasing musculoskeletal rigidity, thereby enhancing the overall quality of life for PD patients¹⁹. Despite the promise shown by these interventions, the current evidence is limited, and there is a pressing need for more large-scale, high-quality research to establish their effectiveness conclusively¹⁷. Moreover, the discussion around the ideal timing for implementing these non-pharmacological treatments highlights the potential benefits of early intervention, suggesting that incorporating these therapies as part of a multidisciplinary approach could be crucial in managing the progressive nature of Parkinson’s disease²⁰.

What is the future direction for developing new treatments for Parkinson’s Disease?

The future direction for developing new treatments for Parkinson’s Disease (PD) is increasingly focused on innovative therapeutic approaches, such as gene therapy, which holds significant potential due to its ability to address the underlying molecular mechanisms of the disease²¹. A particularly promising avenue within gene therapy involves AAV-based strategies that target neurotrophic factors and dopamine production, which have shown encouraging results in preclinical and early clinical trials²¹. This approach could not only modify the course of the disease but also potentially reverse some of its effects, offering hope for more effective management of PD²¹. Moreover, the exploration of targeted drug delivery systems using nanotechnology is anticipated to enhance the precision and efficacy of treatment delivery to affected brain regions, reducing side effects and improving patient outcomes²¹. However, to fully harness these advancements, significant challenges such as optimizing gene delivery, ensuring long-term safety, and efficacy must be addressed, alongside ethical and cost considerations²¹.

DISCUSSION

The findings outlined in this comprehensive review highlight the multifaceted nature of Parkinson’s Disease (PD) and underscore the critical need for an integrative approach to its understanding and management. The significant reduction in dopamine production due to the degeneration of dopaminergic neurons, particularly within the substantia nigra, establishes a clear physiological basis for the motor symptoms associated with PD. This review emphasizes the correlation between the loss of over 80% of dopamine-producing cells in the substantia nigra pars compacta and the onset of clinical symptoms, which suggests that early detection and intervention could be crucial in altering disease trajectories. Furthermore, the exploration of genetic factors, ranging from monogenic to sporadic variants, reveals the complex interplay between genetic predispositions and environmental influences, warranting the development of novel prognostic indices that account for this cumulative risk. Notably, the emerging focus on tau pathology and neuroinflammation as significant contributors to PD pathology broadens our understanding of disease mechanisms and suggests that existing therapeutic strategies targeting alpha-synuclein may need to be reevaluated in light of these new insights. The potential of gene therapy, particularly through AAV-based strategies targeting neurotrophic factors, highlights a promising avenue for not only modifying disease progression but potentially reversing its effects. However, challenges such as optimizing gene delivery systems, ensuring long-term safety, and addressing ethical considerations remain critical hurdles in translational research. Moreover, while existing pharmacological treatments have been effective in managing motor symptoms, they often neglect non-motor symptoms and may lead to adverse effects, emphasizing the need for holistic treatment approaches that incorporate adjunct therapies, such as acupuncture, which have shown promise in alleviating non-motor symptoms. As we advance our understanding of PD, it becomes increasingly apparent that interdisciplinary research combining genetic, environmental, and neurobiological perspectives is essential for developing effective therapeutic interventions and improving patient outcomes. Future studies should prioritize the exploration of gene-environment interactions and their implications for disease progression, as well as the refinement of biomarkers that can facilitate early diagnosis and risk stratification in asymptomatic individuals. Ultimately, these insights could pave the way for more personalized and effective management strategies, addressing both motor and non-motor symptoms and enhancing the quality of life for those affected by Parkinson’s Disease.

CONCLUSIONS

1. Parkinson’s disease (PD) remains a complex and multifaceted neurodegenerative disorder, with significant challenges in understanding its mechanisms and developing effective treatments. This review highlights the substantial progress made in unraveling the pathophysiological underpinnings of PD, including the roles of alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. Genetic insights, particularly those involving mutations in SNCA, LRRK2, and PARKIN, have advanced our understanding of hereditary forms of the disease and opened avenues for targeted interventions.
2. Despite these advancements, the clinical management of PD remains primarily symptomatic, with levodopa and dopamine agonists serving as the cornerstone of treatment. While these therapies effectively alleviate motor symptoms, they are associated with long-term complications such as motor fluctuations and dyskinesias. Emerging pharmacological approaches targeting non-dopaminergic pathways and innovative delivery systems, including extended-release formulations, hold promise for improving symptom control and reducing side effects.
3. Non-pharmacological interventions, including deep brain stimulation (DBS), physical therapy, and occupational therapy, play a critical role in the holistic management of PD. These approaches, particularly DBS, have shown substantial benefits in managing motor symptoms and improving quality of life in appropriately selected patients. Additionally, lifestyle modifications, such as regular exercise and dietary adjustments, contribute to overall well-being and may mitigate some disease symptoms.
4. Research into advanced therapies, including gene therapy, stem cell-based treatments, and immunotherapy targeting alpha-synuclein, represents a promising frontier in PD management. Although these approaches are in early stages, they offer the potential for disease-modifying effects that could fundamentally alter the course of PD. However, challenges such as scalability, safety, and long-term efficacy must be addressed before these therapies become widely available.

REFERENCES

1. American Association of Neurological Surgeons. Parkinson’s Disease [Internet]. AANS. 2024 [cited 2024 Nov 30]. Available from: https://www.aans.org/patients/conditions-treatments/parkinsons-disease/
2. Paris Brain Institute. What are the biological mechanisms of Parkinson’s disease? [Internet]. Paris Brain Institute. 2025 [cited 2024 Nov 30]. Available from: https://parisbraininstitute.org/disease-files/parkinsons-disease/what-are-biological-mechanisms-parkinsons-disease
3. Maiti P, Manna J, Dunbar GL. Current understanding of the molecular mechanisms in Parkinson’s disease: Targets for potential treatments. Translational Neurodegeneration [Internet]. 2017 Oct 25 [cited 2024 Nov 30];6(1). Available from: https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-017-0099-z
4. MedlinePlus. Parkinson’s disease: MedlinePlus Genetics [Internet]. medlineplus.gov. 2012 [cited 2024 Nov 30]. Available from: https://medlineplus.gov/genetics/condition/parkinsons-disease/
5. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. The Lancet Neurology [Internet]. 2020 [cited 2024 Nov 30];19(2):170–8. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8972299/
6. Redenšek S, Trošt M, Dolžan V. Genetic Determinants of Parkinson’s Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect? Frontiers in Aging Neuroscience [Internet]. 2017 Feb 10 [cited 2024 Nov 30];9(1). Available from: https://doi.org/10.3389/fnagi.2017.00020
7. Pang SYY, Ho PWL, Liu HF, Leung CT, Li L, Chang EES, et al. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease. Translational Neurodegeneration [Internet]. 2019 Aug 16 [cited 2024 Nov 30];8(1). Available from: http://web.b.ebscohost.com/ehost/detail/detail?vid=6&sid=2fde67b2-5a92-4258-b46d-3dfbabca3ed8%40pdc-v-sessmgr03&bdata=JkF1dGhUeXBlPWNvb2tpZSxpcCxjdXN0dWlkJmN1c3RpZD1pbmZvaGlvJnNpdGU9ZWhvc3QtbGl2ZSZzY29wZT1zaXRl#AN=138109978&db=aph
8. De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson’s Disease: An Environmental Agenda. Journal of Parkinson’s Disease [Internet]. 2022 Jan 1 [cited 2024 Nov 30];12(1):45–68. Available from: https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd212922
9. Harth R. New research challenges conventional picture of Parkinson’s disease [Internet]. news.asu.edu. 2024 [cited 2024 Nov 30]. Available from: https://news.asu.edu/20240214-science-and-technology-new-research-challenges-conventional-picture-parkinsons-disease
10. Backman I. Parkinson’s Disease Associated with Neuroinflammation in the Brain, New Analyses Reveal [Internet]. Yale School of Medicine. 2024 [cited 2024 Nov 30]. Available from: https://medicine.yale.edu/news-article/parkinsons-disease-associated-with-neuroinflammation-in-the-brain-new-analyses-reveal/
11. Michael J. Fox Foundation for Parkinson’s. Breaking News: Parkinson’s Disease Biomarker Found [Internet]. www.michaeljfox.org. 2023 [cited 2024 Nov 30]. Available from: https://www.michaeljfox.org/news/breaking-news-parkinsons-disease-biomarker-found
12. The Parkinson’s Foundation. Parkinson’s Biomarkers [Internet]. Parkinson’s Foundation. 2023 [cited 2024 Nov 30]. Available from: https://www.parkinson.org/understanding-parkinsons/getting-diagnosed/biomarkers
13. Univerity of Rochester Medical Center. What You Need to Know about the New Parkinson’s Biomarker [Internet]. URMC Newsroom. 2023 [cited 2024 Nov 30]. Available from: https://www.urmc.rochester.edu/news/story/what-you-need-to-know-about-the-new-parkinsons-biomarker
14. Weill Cornell Medicine. Preclinical Model Offers New Insights into Parkinson’s Disease Process [Internet]. WCM Newsroom. Weill Cornell Medicine; 2024 [cited 2024 Nov 30]. Available from: https://news.weill.cornell.edu/news/2024/07/preclinical-model-offers-new-insights-into-parkinson%E2%80%99s-disease-process
15. Anderson C. New Parkinson’s Disease Model Improves Understanding of Disease Progression and Potential Early Detection [Internet]. Inside Precision Medicine. 2024 [cited 2024 Nov 30]. Available from: https://www.insideprecisionmedicine.com/topics/translational-research/new-parkinsons-disease-model-improves-understanding-of-disease-progression-and-potential-early-detection/
16. Zahoor I, Shafi A, Haq E. Pharmacological Treatment of Parkinson’s Disease. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. 2018 Dec 21 [cited 2024 Nov 30];Chapter 7(1):129–44. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536726/
17. Zhang Y, Liu S, Xu K, Zhou Y, Shen Y, Liu Z, et al. Non-pharmacological therapies for treating non-motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis. Frontiers in aging neuroscience [Internet]. 2024 Apr 26 [cited 2024 Nov 30];16(1). Available from: https://doi.org/10.3389/fnagi.2024.1363115
18. Journal of Parkinson’s Disease. Non-Pharmacological Interventions Poised to Play a Greater Role in the Treatment of Individuals with Parkinson’s Disease, Experts Say [Internet]. Journalofparkinsonsdisease.com. 2023 [cited 2024 Nov 30]. Available from: https://www.journalofparkinsonsdisease.com/non-pharmacological-interventions-poised-play-greater-role-treatment-individuals-parkinsons-disease
19. Qureshi AR, Jamal MK, Rahman E, Paul DA, Oghli YS, Mulaffer MT, et al. Non‐pharmacological therapies for pain management in Parkinson’s disease: A systematic review. Acta Neurologica Scandinavica [Internet]. 2021 May 13 [cited 2024 Nov 30];144(2):115–31. Available from: https://pubmed.ncbi.nlm.nih.gov/33982803/
20. Sharpe G, Macerollo A, Fabbri M, Tripoliti E. Non-pharmacological Treatment Challenges in Early Parkinson’s Disease for Axial and Cognitive Symptoms: A Mini Review. Frontiers in Neurology [Internet]. 2020 Sep 25 [cited 2024 Nov 30];11(1). Available from: https://doi.org/10.3389/fneur.2020.576569
21. Bougea A. Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomedicines [Internet]. 2024 Feb 29 [cited 2024 Nov 30];12(3):549. Available from: https://pubmed.ncbi.nlm.nih.gov/38540162/